Search Results
Mar 03, 2026, 15:10 ET Are ACLX, VRE, LSF Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-aclx-vre-lsf-obtaining-fair-deals-for-their-shareholders-302702818.htmlSOURCE
More news about: Halper Sadeh LLP
Feb 23, 2026, 17:22 ET Are ACLX, VRE, UHG, EHAB Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-aclx-vre-uhg-ehab-obtaining-fair-deals-for-their-shareholders-302694886.htmlSOURCE
More news about: Halper Sadeh LLP
Feb 23, 2026, 15:00 ET $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Veris Residential, Inc. (NYSE: VRE)
VRE) related to its sale to an investor consortium led by Affinius Capital in partnership with Vista Hill Partners. Under the terms of the proposed
More news about: Monteverde & Associates PC
Feb 23, 2026, 11:35 ET Shareholder Alert: The Ademi Firm investigates whether Veris Residential Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE, Feb. 23, 2026 /PRNewswire/ -- Ademi LLP is investigating Veris (NYSE: VRE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Affinius Capital.
More news about: Ademi LLP
Feb 23, 2026, 07:21 ET Veris Residential to Be Acquired by Affinius Capital-Led Investor Consortium for $3.4 Billion in Cash
JERSEY CITY, N.J., Feb. 23, 2026 /PRNewswire/ -- Veris Residential, Inc. (NYSE: VRE) ("Veris" or the "Company"), a forward-thinking, Northeast-focused, Class A multifamily REIT, today announced that it has entered into a definitive merger
More news about: Veris Residential, Inc.
Feb 23, 2026, 07:20 ET Veris Residential, Inc. Reports Fourth Quarter and Full Year 2025 Results
VRE Shareof 4Q NOIVRE Shareof
More news about: Veris Residential, Inc.
Feb 16, 2026, 08:01 ET Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update
Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP).To learn more about Acurx Pharmaceuticals and its product pipeline, please visit
More news about: Acurx Pharmaceuticals, Inc.
Feb 05, 2026, 08:30 ET Veris Residential, Inc. Announces Dates for Fourth Quarter and Full Year 2025 Financial Results and Webcast
N.J., Feb. 5, 2026 /PRNewswire/ -- Veris Residential, Inc. ("Veris Residential" or the "Company") (NYSE: VRE), a forward-thinking, Northeast-focused, Class A multifamily REIT, today announced that it will host its fourth quarter and full year 2025 financial results
More news about: Veris Residential, Inc.
Feb 02, 2026, 08:00 ET USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Acurx's lead product candidate,
More news about: Acurx Pharmaceuticals, Inc.
Jan 26, 2026, 16:15 ET Veris Residential Announces Tax Treatment of 2025 Distributions
JERSEY CITY, N.J., Jan. 26, 2026 /PRNewswire/ -- Veris Residential, Inc. (NYSE: VRE) (the "Company"), a forward-thinking, Northeast-focused, Class A multifamily REIT, today announced the tax treatment of its 2025 Distributions. The Company's
More news about: Veris Residential, Inc.
Dec 09, 2025, 16:15 ET Veris Residential Completes $75 Million Sale of Harborside 8/9 Land Parcel
JERSEY CITY, N.J., Dec. 9, 2025 /PRNewswire/ -- Veris Residential, Inc. (NYSE: VRE), (the "Company"), a forward-thinking, Northeast-focused, Class A multifamily REIT, today announced that it has sold its 4.2-acre Harborside 8/9 land
More news about: Veris Residential, Inc.
Nov 18, 2025, 08:00 ET Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals
inhibitor from Acurx's portfolio. The results of this work, which include kinetic data for a suite of Acurx lead compounds versus the polymerases of MRSA, VRE and PRSP and three complete structures (apo-PolC, PolC in complex with ibezapolstat and PolC in complex with ACX-801), were published in Nature Communications
More news about: Acurx Pharmaceuticals, Inc.
Nov 12, 2025, 07:01 ET Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update
in each case, which cover the ACX-375C program, relating to DNA Pol IIIC Inhibitors for infections caused by Gram-positive bacteria including MRSA, VRE and PRSP, with other country-level filings in process. Also in September 2025, at our special meeting of stockholders, our
More news about: Acurx Pharmaceuticals, Inc.
Nov 10, 2025, 08:00 ET Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens
class of antibiotics, the first in more than 30 years, that target a critical enzyme of Gram-positive bacteria including C. difficile, MRSA, VRE and PRSP (penicillin-resistant Streptococcus pneumonia) Acurx's lead DNA pol IIIC antibiotic, ibezapolstat (IBZ), has
More news about: Acurx Pharmaceuticals, Inc.
Nov 05, 2025, 08:30 ET Veris Residential Declares Fourth Quarter 2025 Cash Dividend
JERSEY CITY, N.J., Nov. 5, 2025 /PRNewswire/ -- Veris Residential, Inc. (NYSE: VRE) ("Veris Residential" or the "Company"), a forward-thinking, Northeast-focused, Class A multifamily REIT, today announced that the Company's Board of
More news about: Veris Residential, Inc.
Nov 03, 2025, 10:33 ET Lakewood-Amedex Biotherapeutics to Participate in Panel Discussion at BioFlorida's "Florida Innovation Conference"
Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. Antimicrobial resistance (AMR) represents a growing global health crisis, contributing to nearly 5 million deaths worldwide. The company's
More news about: Lakewood-Amedex Biotherapeutics Inc.
Oct 29, 2025, 15:08 ET Silver Wound Dressing Market to Reach USD 2,129.8 million by 2032, Growing At An 4.19% CAGR - Credence Research
into the wound bed. Silver ions are highly effective at killing a broad spectrum of pathogens, including antibiotic-resistant bacteria like MRSA and VRE, as well as fungi and yeasts. By controlling the microbial load in a wound, these dressings help to prevent and treat localized infections, reduce inflammation,
More news about: Credence Research Inc.
Oct 28, 2025, 08:00 ET Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference
Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Acurx's lead product candidate,
More news about: Acurx Pharmaceuticals, Inc.
Oct 27, 2025, 08:00 ET Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update
Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). To learn more about Acurx Pharmaceuticals and its product pipeline, please
More news about: Acurx Pharmaceuticals, Inc.
Oct 22, 2025, 16:39 ET Veris Residential, Inc. Reports Third Quarter 2025 Results
JERSEY CITY, N.J., Oct. 22, 2025 /PRNewswire/ -- Veris Residential, Inc. (NYSE: VRE) (the "Company"), a forward-thinking, Northeast-focused, Class A multifamily REIT, today reported results for the third quarter 2025.
More news about: Veris Residential, Inc.
Oct 22, 2025, 08:33 ET Lakewood-Amedex Biotherapeutics Announces Peer-Reviewed Publication Demonstrating Potent Antimicrobial Activity of Bisphosphocin® Class Against Resistant Pathogens
Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. Antimicrobial resistance (AMR) represents a growing global health crisis, contributing to nearly 5 million deaths worldwide. The company's
More news about: Lakewood-Amedex Inc.
Oct 09, 2025, 07:30 ET Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
transform the antibiotic treatment paradigm to combat multidrug-resistant Gram-positive pathogens such as Staphylococcus aureus, including MRSA, VRE, and PRSP; furthermore, these compounds are expected to be active against B. anthracis or anthrax, a Bioterrorism Category A Threat-Level pathogen".
More news about: Acurx Pharmaceuticals, Inc.
Oct 08, 2025, 11:15 ET Potomac Shores Reaches Project Milestones as Retail Opportunities Expand
designed to accommodate as many as five retail tenants, including an anchor restaurant. The 20,000 square-foot Station House features a pass-through for VRE Station access and more than 15,000 square-feet of retail space over two levels. The 8,500 square-foot upper level is planned as restaurant space, with
More news about: Biddle Real Estate Ventures
Oct 06, 2025, 08:30 ET Veris Residential, Inc. Announces Dates for Third Quarter 2025 Financial Results and Webcast
CITY, N.J., Oct. 6, 2025 /PRNewswire/ -- Veris Residential, Inc. ("Veris Residential" or the "Company") (NYSE: VRE), a forward-thinking, Northeast-focused, Class A multifamily REIT, today announced that it will host its third quarter 2025 financial results webcast
More news about: Veris Residential, Inc.
Sep 30, 2025, 08:33 ET Lakewood-Amedex Biotherapeutics to Present at BioFlorida Regional Event at The Roskamp Institute
Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. Antimicrobial resistance (AMR) represents a growing global health crisis, contributing to nearly 5 million deaths worldwide. The company's
More news about: Lakewood-Amedex Inc.